Trial Profile
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of Inhaled Iloprost in Patients With Pulmonary Arterial Hypertension Receiving Oral Sildenafil
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Iloprost (Primary) ; Bosentan; Sildenafil
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms VISION
- Sponsors Actelion Pharmaceuticals; CoTherix
- 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 31 Jul 2021 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 29 Mar 2014 New trial record